A C.D.C. panel will meet today on the Johnson & Johnson vaccine pause.
The U.S. government is likely to end the pause if the panel says the vaccine’s benefits outweigh the potential risk.
View original article
Contributor: Carl Zimmer
The U.S. government is likely to end the pause if the panel says the vaccine’s benefits outweigh the potential risk.
View original article
Contributor: Carl Zimmer